|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Surveillance of children with chronic liver diseases with ultrasound and alpha-fetoprotein may be helpful in timely detection, intervention and overall improvement in outcome of HCC.
|
30254403 |
2018 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Seventy-nine patients had NTM-RFA and 62 had SR. After IPTW, the two groups were well-balanced for most baseline characteristics including tumor size, location, etiology, severity of underlying liver disease and alpha-fetoprotein level.
|
29410287 |
2018 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Compared to each biomarker alone, the combination of AFP and PIVKA-II with age and gender improved the accuracy of detecting HCC and differentiating HCC from non-malignant liver disease.
|
30675135 |
2019 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, in two-thirds of hepatoma patients the AFP profile was different from the profile observed in patients with benign liver disorders.
|
6171874 |
1981 |
|
Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Other liver diseases including cirrhosis and chronic hepatitis are related with an increased level of AFP.
|
19968979 |
2010 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Although the level of AFP is increased in HCC, its sensitivity for diagnosis is poor because AFP levels are also increased in liver diseases.
|
29888876 |
2018 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In comparison to serum α-fetoprotein (AFP) level, which remains the gold standard for HCC diagnosis, high serum DKK1 levels have higher diagnostic value for HCC, especially for AFP-negative HCC, and can distinguish HCC from non-malignant chronic liver diseases.
|
24809435 |
2014 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Serum levels of liver enzymes, such as alanine transaminase, aspartate transaminase, and α-fetoprotein, provide insight into liver function and are used during treatment of liver disease, but such information is limited.
|
26927063 |
2016 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein elevation has been associated with chronic liver diseases and a limited number of cancers.
|
28407756 |
2017 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Central venous blood of patients with HCC (n = 24) and patients with benign liver diseases (n = 13) equally demonstrated AFP-expressing cells.
|
10668884 |
2000 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
CTD_human |
AFP-positive and AFP-negative carcinomas occurred in the same liver.
|
16965562 |
2006 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our study aims to detect the sensitivity of the new biomarker miR-212 existing in serum exosomes along with other hepatocellular carcinoma biomarkers such as AFP (alpha-fetoprotein), CA125 (carbohydrate antigen-ca125), and Hbx protein in the diagnosis of HBV-related liver diseases.
|
31608838 |
2019 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
AKT, BCL2 and IL-6 showed normal, reduced and overexpression in studied patients with a significant difference between AFP, AKT overexpression (67% and 30%), BCL2 overexpression (49% and 10%) and reduced IL-6 in between HCC and LD.
|
19054267 |
2009 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
AFP could still be a reliable tool in diagnosis and prognosis of HCC patients especially in developing countries due to its relevant association with aspects of advanced tumor and liver disease, gender and a poor functional status.
|
31263843 |
2019 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Human liver carboxylesterase 1 outperforms alpha-fetoprotein as biomarker to discriminate hepatocellular carcinoma from other liver diseases in Korean patients.
|
23319432 |
2013 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, the combination of serum miR-182, miR-331-3p, and alpha-fetoprotein (AFP) can markedly increase the differential diagnostic value of benign and malignant liver diseases, especially better than serum AFP alone, P < 0.05.
|
25903466 |
2015 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
However, it has been indicated that AFP-L3 and DCP excel AFP in differentiating hepatocellular carcinoma from nonmalignant hepatopathy and detecting small hepatocellular carcinoma.
|
16534867 |
2006 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Collagen IV, hyaluronic acid, platelet-derived growth factor (PDGF) and tissue inhibitor of metalloproteinase-1 (TIMP-1) were measured by ELISA, and AST, ALT, platelet count, albumin, total bilirubin, INR and AFP by routine methods in 148 patients with hepatitis C induced liver disease.
|
28945150 |
2018 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
There was a significant interaction between AFP category and etiology of liver disease (P < 0.001).
|
30362249 |
2019 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DNA ploidy did not show any correlation with age, sex, alcohol abuse, hepatitis B virus, serum alpha-fetoprotein level or underlying liver disease.
|
1322756 |
1992 |
|
Liver diseases
|
0.400 |
GeneticVariation
|
group |
BEFREE |
We performed RT-PCR to detect the expression of hTERT mRNA in 78 patients with HCC, 10 with liver cirrhosis (LC), 12 with chronic hepatitis (CH), and 34 healthy individuals without any liver diseases and cancers, and statistically analyzed the association with clinical parameters which include age, sex, etiology, Child classification, underlying liver disease, biochemical data, alpha-fetoprotein (alpha-AFP) number and size of tumor, and histological differentiation of HCC regarding HCC patients.
|
12759542 |
2003 |
|
Liver diseases
|
0.400 |
AlteredExpression
|
group |
BEFREE |
A preliminary high sensitivity chemiluminescence enzyme immunoassay kit showed increased levels of fucosylated AFP in the sera of patients with HCC, but not in the sera of normal patients, or patients with chronic liver diseases.
|
31451706 |
2019 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Our data indicate that the combination of AFP and NLR offers better diagnostic performance than either marker alone for differentiating HCC from liver disease, which may benefit clinical screening.
|
30545306 |
2018 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
Alpha-fetoprotein (AFP) has been shown to predict the prognosis of liver disease in several studies.
|
29300103 |
2018 |
|
Liver diseases
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, the combination of dual serum fluorescence, AFP, hepatic function tests and age is simple and valuable for identifying HCC in serum AFP-elevated liver diseases.
|
29228649 |
2017 |